MPM Capital-backed TCR2 Therapeutics To Go Public

“We are delighted to have such a strong group of investors as we transition into a clinical-stage company. They have recognized our unique ability to target both solid and hematological cancers using a TCR approach that is not HLA dependent,” said Dr. Garry Menzel, Chief Executive Officer of TCR2...